论文信息 - Dynamic BH3 profiling-poking cancer cells with a stick

Dynamic BH3 profiling-poking cancer cells with a stick

ABSTRACT The vast majority of efforts in precision medicine for cancer try to link static genetic information to tumor biology and from there predict clinical response. Dynamic BH3 profiling offers an alternative functional approach by measuring death signaling induced by specific drugs in tumors from patients ex vivo to predict clinical response.

A. Letai | J. Montero | Joan Montero | Anthony Letai

[1] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[2] A. Letai,et al. Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[3] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[4] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[5] A. Letai,et al. BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[6] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[7] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[8] Michael B Yaffe,et al. The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment , 2013, Science Signaling.

[9] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[10] S. Armstrong,et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.